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Abstract: River blindness is a seriously debilitating
disease caused by the filarial parasite Onchocerca volvulus,
which infects millions in Africa as well as in South and
Central America. Research has been hampered by a lack of
good animal models, as the parasite can only develop
fully in humans and some primates. This review highlights
the development of two animal model systems that have
allowed significant advances in recent years and hold
promise for the future. Experimental findings with
Litomosoides sigmodontis in mice and Onchocerca ochengi
in cattle are placed in the context of how these models
can advance our ability to control the human disease.
Introduction
Infection with Onchocerca volvulus, a filarial nematode, can lead to
debilitating skin disease and blindness (river blindness). Adult
worms live in subcutaneous nodules; however, the pathology of
onchocerciasis is primarily associated with death of microfilariae
larvae in the skin and eyes (Figures 1 and 2). It is estimated that 37
million people are infected with O. volvulus [1], over 99% of whom
live in West and Central Africa, although there are significant foci
in South and Central America. Early attempts at control of
onchocerciasis relied on treatment of water courses with
insecticides to kill the larvae (larviciding) of the blackfly (Simulium
spp.) vectors. Using this approach for over 25 years, the WHO/
UNDP Onchocerciasis Control Programme (OCP) reduced the
burden of disease in savannah regions of West Africa [2,3]. In
1987, ivermectin (Mectizan, Merck & Co.) was introduced for
mass treatment of onchocerciasis either alone or in combination
with larviciding. The OCP closed in December 2002, and control
of onchocerciasis now relies on community-based treatment with
ivermectin implemented through the African Programme for
Onchocerciasis Control (APOC) [4]. The Onchocerciasis Elimi-
nation Programme for the Americas similarly distributes Mectizan
twice a year in its target countries of Brazil, Colombia, Ecuador,
Guatemala, Mexico, and Venezuela [5].
Ivermectin is very effective at killing microfilariae and has
proved successful in reducing morbidity within the community and
the risk of severe skin or ocular disease for the individual.
However, its macrofilaricidal activity (i.e., efficacy against adult
parasites) is, at best, slow and partial, necessitating the use of
repeated drug administration for several years [6–8]. Furthermore,
early hopes that mass treatment with ivermectin would eradicate
the disease by breaking transmission have not been realised [2]
because of inadequate treatment coverage, migration, and
recrudescence of infections in areas where treatment has been
suspended. In addition, there is mounting evidence that resistance
to ivermectin is emerging [9–13]. Such circumstances require
development of complementary measures to sustain even the
current levels of control, let alone eliminate the disease. What are
needed is a safe and effective macrofilaricide and a vaccine.
A major obstacle facing onchocerciasis research and, particu-
larly that concerned with vaccine development, has been the
absence of good animal models. Use of mice was limited because
they are unable to support cyclical development of filariae species.
All rodents are strictly non-permissive to O. volvulus, which can
develop only in primates, and thus studies of protective immunity
in mice involve implantation of infective stage larvae (L3) into
subcutaneous chambers [14]. Mice are somewhat more permissive
to Brugia species (causative agents of lymphatic filariasis) but still do
not allow natural tissue migration or development of circulating
microfilariae. Patent infections with circulating microfilariae can
be established in the Mongolian gerbil (Meriones unguiculatus) with
Brugia species and Acanthocheilonema viteae; however, the absence of
reagents places serious restrictions on immunological investigation.
Nonetheless, despite limitations, these models have made signif-
icant contributions to our knowledge of filarial infections (reviewed
in [14–16]) and provided a basis of more recent investigations
using two new models.
The first is Litomosoides sigmodontis (Table 1), a natural parasite of
the cotton rat (Sigmodon hispidus) that in the early 1990s was found
to undergo complete development in BALB/c mice and produce
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patent infections with circulating microfilariae within 55–60 days
post-infection [17]. Development of L. sigmodontis in other inbred
strains is restricted. For example, in C57BL/6 mice, filariae are
progressively killed and never produce a patent infection. It is now
possible to utilise the full power of murine immunology to study
the interaction of filarial parasites with their hosts at all stages of
the parasite’s development from migration of infective larvae to
the production of microfilariae. The ability of L. sigmodontis to
achieve patency allows a comparison to human studies not possible
in other murine models. The data thus far show a striking
similarity to human studies, particularly in the context of
regulation (discussed below); thus, through experimental manip-
ulation, this model can provide mechanistic explanations of
susceptibility and resistance not possible in any other system.
The second model is Onchocerca ochengi in cattle (Table 1;
Figure 3). This is the closest known relative of the human parasite
and is also transmitted by the blackfly, Simulium damnosum sensu lato.
O. ochengi is confined to Africa and combines many important
features of the human infection [18]. Most importantly, O. ochengi
forms nodules that closely resemble those of O. volvulus and which
can be enumerated non-invasively or removed for analysis during
immunological or chemotherapeutic studies. Furthermore, puta-
tive immune animals exist naturally in endemic areas and exhibit
demonstrable resistance to infection [19]. The O. ochengi model
thus provides the unique opportunity to undertake controlled
experiments, both laboratory-based and under natural challenge
in the field, that are not possible in humans.
The main drawback to both of these model systems is that they
do not allow the investigation of disease pathology relevant to
human onchocerciasis. This work will continue to rely on either
human field studies or experimental exposure of mice to Onchocerca
antigens in a model of ocular disease [20].
Figure 1. Life cycle of Onchocerca volvulus and Onchocerca ochengi. Adult female worms initiate the formation of nodules in the skin
(onchocercomas) (see Figures 2 and 3) in which their highly coiled bodies can reach a length of approximately 25 cm, while the males are a little over
1/10th that length. Transverse sections of adult female worms in the onchocercoma are shown in (A). Following mating, embryos develop inside the
female, which gives birth to motile L1 larvae that are known as microfilaria (MF). A transverse section of an adult female with MF in utero is shown in
(B); Wolbachia in lateral hypodermal chords (*) of the adult female and uterine microfilaria (arrows) are stained red. MF migrate into the dermis
(shown in [C]), where they are available for transmission to the simuliid blackfly vector (shown in [D]). Within the fly, MF develop further as L1 larvae
and molt into second-stage larvae, which molt again to become the infective L3 larvae (7 days). The L3 enter the skin through the wound caused by
the feeding fly. The blackfly requires fast moving water to breed and thus infection occurs adjacent to rivers. Adult female worms live for several years
and individuals (people or cattle) can remain microfilaraemic for their entire lives if repeatedly exposed to infection. (Photo credits: M. Boussinesq, S.
Spetch, J. Allen, O Bain, S. Wanji, S. Uni)
doi:10.1371/journal.pntd.0000217.g001
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Mechanisms of Parasite Killing
In the L. sigmodontis model, innate responses at the inoculation site
are associated with destruction of a majority of L3s in the
subcutaneous tissue within 2 days post-infection. However, about
one-third of L3 larvae avoid this attack by entering lymphatic vessels
[21,22], a strategy characteristic of many human filariae [23,24].
The number of larvae that survive this early stage varies depending
on sex and strain of the host [25], but is unaffected by the size of the
initial inoculum [26]. From Day 4 post-inoculation, surviving L3
begin to appear in the pleural cavity of L. sigmodontis–infected mice.
Differences in the pattern of development of the parasites in resistant
C57BL/6 and susceptible BALB/c mice appear early and get
progressively more apparent [25]. By 30 days post-infection, about
one-third of the population in C57BL/6 mice are still at the L4 stage;
this contrasts with ,15% in susceptible BALB/c mice [27].
Furthermore, worms recovered from the C57BL/6 mice are smaller
than those from BALB/c mice. Analysis of cytokine production at
this time shows mixed T helper cell type 1 (Th1)-Th2 response in the
C57BL/6 mice reminiscent of that observed in putative immune
human patients [28]. In BALB/c mice, the cytokine response is more
biased towards Th2 (see Box 1).
The ability of filarial parasites to induce Th2-type immune
responses is well documented, but whether this bias is detrimental
or beneficial for the parasite is not always clear. However,
infection of IL-4–deficient C57BL/6 mice leads to full parasite
development and patency, indicating that a Th2 response is the
key determinant of resistance in these non-permissive mice [29].
Consistent with a role for type 2 immunity in parasite killing,
partially resistant 129/SvJ mice with a genetic deficiency in either
major basic protein or eosinophil peroxidase were found to
harbour several times more adult worms than their wild-type
littermates [30]. Further, BALB/c mice deficient in IL-4, IL-5, or
IL-4Ra (unable to respond to IL-4 or IL-13) present with levels of
microfilariae 100 times higher than wild-type controls [31,32].
This evidence that type 2 cytokines can control microfilarial levels
is consistent with studies on Brugia species [33].
Although the data began to build a convincing argument for
Th2 control of filarial infections, the picture that emerged proved
more complex. The BALB/c IL-4Ra–deficient mice presented a
paradox, for although the mice had enormously increased
numbers of circulating microfilaria relative to wild-type mice,
death of the adult parasites was accelerated. Examination of the
effector cells at the site of infection demonstrated that the mice had
converted to a Th1 phenotype suggesting that a pro-inflammatory
Figure 2. Subcutaneous Nodules on a Child in Ghana. Photo
credit: P. Soboslay.
doi:10.1371/journal.pntd.0000217.g002
Table 1. General Features of the Biology of O. volvulus, O. ochengi, and L. sigmodontis
Filariae Vector
Time to
Patency Adult Mf Disadvantages Advantages
O. volvulus Blackfly, Simulium spp. 250–375 days Subcutaneous nodules Skin Experimentation not
possible
The target organism
O. ochengi Blackfly, Simulium spp. From 250 days Intradermal nodules Skin Outbred animals, no
pathology
–Very closely related to O. volvulus
–Experimentation under natural challenge
–Infection quantifiable
L. sigmodontis Tropical rat mite,
Ornithonyssus bacoti
,50 days Thoracic cavity Blood Not skin dwelling, no
pathology
–All stages of the life cycle accessible for
experimentation
–Power of murine immunology
–Protective immunity evoked by
vaccination
doi:10.1371/journal.pntd.0000217.t001
Figure 3. Intradermal Nodules Containing Adult Onchocerca
ochengi on Ventral Hide of a Naturally Infected Cow (Bos
indicus) in Cameroon. Photo credit: A. J. Trees.
doi:10.1371/journal.pntd.0000217.g003
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type 1 response was capable of killing the adult parasite (J. Allen
and M. G. Nair, unpublished data). Consistent with this, more
adult worms are recovered from mice genetically deficient in the
type 1 cytokine, IFN-c [34,35] Indeed, IFN-c and IL5 appear to
act synergistically to destroy adult parasites [34,36]. Thus,
although Th2 responses seem capable of mediating destruction
of the larval stages, both Th1 and Th2 may be needed to contain
the more resilient adult stage.
Induction of a Th1 response may be a consequence of the
presence of the endosymbiont bacterium Wolbachia found in most
human-pathogenic filariae [37]. Filarial-infected humans, cattle, and
mice demonstrate significant immune responses to the major surface
protein (WSP) of the bacteria [38,39] (B. Makepeace and A. Trees,
unpublished data). Further, WSP as well as the bacteria in total have
been shown to stimulate a typical TLR-dependent inflammatory
response with induction of IL-6, TNF, etc. by macrophages [40–42]
and exhibit potent chemotactic activity for neutrophils [41]. Mice
with a natural mutation of TLR4 (C3H/HeJ) show a higher degree
of susceptibility to L. sigmodontis infection [43]. This is consistent with
protection studies in the O. volvulus mouse chamber model that
identified a TLR4-dependent larval killing mechanism, albeit with
no evidence for Wolbachia involvement [44]. The costs and benefits of
symbiosis with Wolbachia for filariae in terms of manipulation of host
immune responses have yet to be investigated in depth. However,
elimination of Wolbachia from O. ochengi leads to a profound reduction
in local neutrophilia in the nodule and a marked infiltration of
eosinophils, which degranulate on the cuticle of adult worms prior to
parasite death [45]. This is compatible with a potential role for
Wolbachia in modulating the anti-nematode response.
Regulation
Although a clearer picture of how mammalian hosts can kill
filarial nematodes is emerging, in a successful infection these
mechanisms fail. Human studies have long since demonstrated
that filarial parasites induce a state of hypo-responsiveness in the
host that is associated with the presence of circulating microfilaria
[46]. Both the L. sigmodontis and O. ochengi models can mimic this,
with Th1 and Th2 cytokines down-regulated coincident with the
onset of patency [47,48]. Intrinsic defects in T cell responses in
human filarial infection are linked with expression of the T cell–
inhibiting receptor, CTLA-4 [49], and neutralisation of CTLA-4
in mice results in enhanced L. sigmodontis killing [50]. In addition to
this intrinsic T cell hypo-responsiveness, T cell responses in
humans can be dampened by suppressive antigen-presenting cells
[51]. Both mechanisms are operative in the L. sigmodontis model
where macrophages that block proliferation of T cells are present
at the site of infection prior to patency but become apparent in the
draining lymph nodes only following patency [52]. Studies in
susceptible BALB/c mice have now directly demonstrated that L.
sigmodontis survival is dependent on the induction of a regulatory T
cell population that induces hypo-responsiveness [48]. This
corroborates the data from human field studies demonstrating
that T regulatory (Treg) cells can be isolated from onchocerciasis
patients [53], and generalised onchocerciasis is associated with
antigen-specific Treg cells that can be found in nodules [54].
These studies demonstrate the utility of the L. sigmodontis model to
reveal details of protective and regulatory mechanisms that can
help explain observations made in human infections.
The importance of immune regulation in parasite survival is
also illustrated by the study of mechanisms that determine
microfilarial survival. Different inbred strains of mice differ widely
in their capacity to eliminate circulating microfilariae, and these
genetically determined differences can be attributed to a single
gene locus [55]. However, irrespective of host genetic background,
microfilarial density is regulated by the adult female [56]. An
immune regulatory environment with interleukin 10 (IL-10) as a
key player is induced by the female parasite to facilitate the
survival and persistence of her offspring [56]. In the absence of IL-
4, normally resistant C57BL/6 mice develop patent infection, but
the additional knock-out of IL-10 reverts mice back to a resistant
phenotype [57]. This suggests that IL-10 is inhibiting an anti-
worm effector response that is redundant when a full Th2 response
is in place. In this scenario, wild-type C57BL/6 are non-permissive
because Th2 immunity prevents worm development and patency.
Box 1. Th1 & Th2 Immunity
Helminth parasites are typically associated with the
induction of CD4+ T helper 2 (Th2) cells, while microbial
pathogens induce Th1 responses. Filarial parasites consti-
tute a unique stimulus to the immune system, as they are
worms that (in most cases) contain endosymbiotic bacteria
(Wolbachia). The Th1 response functions to activate
macrophages to be more efficient at microbial destruction
and is essential to survive infection with many intracellular
pathogens such as Mycobacteria and Salmonella. The Th2
response is involved in expelling worms from the
intestines as well as encapsulating and destroying
multicellular parasites. The Th2 response also plays a key
role in wound healing and allergic reactions. Macrophages
are mediators of both Th1 and Th2 immunity but exhibit
different functions. Mast cells and eosinophils are depen-
dent on Th2 cytokines for expansion and recruitment. Th1
and Th2 responses are also associated with differing
antibody isotype profiles, with Th1 cytokines promoting
cytophilic antibodies while Th2 responses promote anti-
bodies involved in allergic-type responses such as IgE. In
addition to T helper cells, T regulatory subsets exist that
function primarily to prevent host damage caused by
overactive effector responses. These are associated with
the production of TGF-b and/or IL-10. Neutrophils, not
pictured here, are phagocytic cells of the innate immune
system that may become activated prior to Th1/Th2
polarisation, but are also strongly associated with a fourth
CD4+ T helper subset: Th17 cells. Th17 cells are strongly
pro-inflammatory and have roles in mediating autoim-
mune disease as well as protection against extracellular
bacteria and may exacerbate pathology during helminth
infection (for a review of T helper subsets in helminth
infection, see Dı´az and Allen [87]).
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In the absence of IL-4, patency occurs because Th2-dependent
mechanisms are absent but IL-10 is present, suppressing
alternative, potentially innate, effector responses. In the absence
of both cytokines, IL-10 restraint of innate mechanisms is lifted
and once again worms are targeted by the immune response.
Consistent with a role for IL-10 in suppressing effector responses,
transgenic overexpression of IL-10 in macrophages in genetically
resistant FVB mice leads to patency [36]. Design of effective
vaccines must take into account that destruction of each parasite
stage may require activation of distinct effector pathways and that
the parasites themselves induce powerful regulatory networks to
modulate these pathways.
Vaccine-Mediated Immunity
The ability of irradiated L3 to generate protection in naı¨ve
animals challenged experimentally with normal larvae has been
demonstrated in numerous models of filariasis [14,58], including
both the L. sigmodontis [21,58,59] and O. ochengi models [19]. The
protective efficacy of irradiated L3 has been successfully translated
into a field trial using O. ochengi in cattle in which significantly lower
worm burdens were observed in vaccinated animals compared to
controls after almost 2 years of continuous exposure to intense
natural challenge from infected Simulium [19]. This success contrasts
with the failure of cattle to develop immunity after drug-abbreviated
infections. When naı¨ve, infection-free calves were exposed to
sustained and intensive levels of natural challenge, monthly or 3-
monthly prophylaxis with macrocyclic lactones completely prevent-
ed the development of adult worms. However, when chemotherapy
ended but exposure continued, these animals were found to be more
susceptible to infection than previously unexposed controls [60] both
in terms of adult numbers and microfilarial levels. Similarly,
following successful macrofilaricidal treatment of pre-existing patent
infections with melarsomine [19] or oxytetracycline [61], cattle were
fully susceptible to re-infection. These data suggest that parasite
death is an insufficient stimulus for the induction of protective
immunity and highlight the importance of defining the mechanisms
by which irradiated L3 induce protection.
The L. sigmodontis system allows the careful study of vaccine-
mediated protection, including larval migration as early as 6 hours
post-infection or challenge, as well as the impact on subsequent
development and ability to develop patent infection. Immune
protection generated by irradiated L. sigmodontis larvae leads to
rapid destruction of the challenge larvae in the subcutaneous tissue
[21,62] and protection is long-lived [63]. Studies with gene-
deficient mice showed that vaccination success depends on IL-5
and antibody [22,59], and this is consistent with observations made
using the O. volvulus mouse chamber model [64]. Evidence suggests
that the pattern of migration of irradiated L3 does not differ from
that of untreated L3 in the first 2 weeks of infection [62]. Further,
in normal infections a high proportion of incoming larvae die and
yet this does not afford protection to re-infection. These findings
argue against protection as a consequence of premature parasite
death or aberrant migration. L3 larvae of filarial parasites are
known to induce regulatory pathways [65], and irradiated L3 may
be failing to produce molecules that initiate downregulatory
pathways in the host. Conversely (but not mutually exclusive)
irradiated larvae may be failing to shut down the expression of
early genes and thus potentially overexpress immunogenic
molecules. Powerful genomic and proteomic tools are now
available to address this question and to this end, extensive
expressed sequence tag (EST) analysis of L. sigmodontis stage-specific
genes is well underway [66,67], which will help to identify both
targets of immunity as well as potential immune regulators.
Because disease is associated with the microfilarial stage in
onchocerciasis and because this stage is the key to transmission, an
anti-microfilarial vaccine also needs to be considered. Indeed,
vaccination with microfilariae of O. lienalis in a bovine system was
shown some years ago to enhance the clearance of microfilariae
subsequently transplanted into the same animal [68]. Moreover, in
natural infections of cattle with O. ochengi, skin microfilarial density
falls with age in spite of increasing numbers of fecund female
worms, which suggests a level of stage-specific microfilarial
immunity may develop [69]. Similar experiments using mice as
a surrogate host of O. volvulus demonstrated that microfilariae of
the human parasite are vulnerable to immune killing and that
these responses can be evoked by related species; in this case, O.
lienalis [70]. However, what is also clear is that female worms can
and do modulate these protective responses [56], and that for any
anti-microfilarial vaccine to be effective it must target these
parasite regulatory molecules as well as the microfilarial antigens.
While there are many reports identifying potential regulatory
molecules [71], the search is by no means over. Identification of
both parasite-derived immunomodulators and the relevant
microfilarial-specific targets is now being facilitated by the filarial
genome project [72] and L. sigmodontis EST analysis [66]. The L.
sigmodontis and O. ochengi models offer powerful complementary
systems to test these candidates in carefully controlled laboratory
settings and field settings under natural challenge.
Alternative Treatments Targeting Wolbachia
Control of onchocerciasis in Africa relies on mass distribution of
microfilaricidal ivermectin. Given the impossibility of onchocer-
ciasis eradication with ivermectin alone [2] and rising concerns
about resistance to this drug [9–13], there is a more pressing need
to identify complementary therapy using existing drugs. The
development of a new drug, apart from the enormous costs, would
take 15 years or more to be completed.
Attention has focused on Wolbachia, the bacterial endosymbionts
found in most filarial species, as a potential target [73,74]. Studies
with L. sigmodontis have established that both rifampicin [75] and
tetracyclines cause growth retardation and sterilisation of adult
worms, but in the latter case daily treatment for at least for 4 weeks
is required [76]. In cattle, long-term, intermittent antibiotic
chemotherapy with oxytetracycline is macrofilaricidal and worm
death is preceded by a considerable reduction in Wolbachia [77]. In
contrast, short-term, intensive treatment (daily therapy for 2
weeks) induces only transient and inconsequential effects on
Wolbachia numbers and is not macrofilaricidal [78]. In humans, 6
weeks of treatment with 100 mg per day of doxycycline has
resulted in a complete inhibition of embryogenesis from between
18 [74,79,80] and 24 months [73]. Logistical considerations and
compliance will demand shorter regimes if tetracyclines are to find
their way into routine use against onchocerciasis. One approach
will be to identify combination therapies. Given that an added
benefit of long-lasting sterilisation of female worms will be
interruption of transmission, research in this area should be
considered a priority. Importantly, the most recent results show
that increasing the dose of doxycycline to 200 mg also exhibits a
strong macrofilaricidal effect in human onchocerciasis [81,82].
However, it must also be recognised that there are restrictions on
use of this class of antibiotics in young persons and pregnant
women. Nevertheless, these observations have intensified
strategies to exploit the Wolbachia genomes for improved antibiotic
targeting [83]. In addition, for final local elimination, e.g., in
foci in the Americas, anti-wolbachial chemotherapy is being
considered [81].
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Targeting Wolbachia may also resolve the problem of ivermectin
use in areas where onchocerciasis and loiasis are co-endemic and
where mass treatment is often discouraged because of severe
adverse reactions that result from the rapid destruction of Loa loa
microfilariae in the central nervous system [84,85]. L. loa does not
possess endosymbiont Wolbachia [86], and therefore a therapy that
targets the bacteria in O. volvulus should have no effect on L. loa.
Targeting Wolbachia is arguably the only approach currently
available (apart from suramin treatment in a hospital) to treat
potentially resistant strains of O. volvulus.
Conclusions
Ten years ago, the mechanisms by which filarial nematodes are
killed by the mammalian host were largely unknown. Although
fine detail of these processes remain to be determined, the animal
models have now allowed us to determine conclusively that Th2
responses drive protective immunity against L3 larvae as well as
the microfilarial stage. Bigger weaponry that includes a Th1 pro-
inflammatory component may be needed to tackle the adult stage.
However, in successful infections all these mechanisms fail because
of the ability of the parasite to initiate regulatory pathways.
Bypassing this regulation may be the key to development of a
vaccine and future disease control. This will require a thorough
understanding of how the parasite induces regulation and
identification of the targets and processes that mediate a protective
but non-pathological response. In the meantime, the prospect of
developing new drug regimes using antibiotics to complement
ivermectin treatment and to achieve a macrofilaricidal activity
may mitigate against problems of emerging drug resistance and
offer new therapy in cases where ivermectin is contra-indicated.
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tion on a particular topic that may not be recalled by a
‘‘filaria*’’ search (for example, ‘‘ivermectin resistance’’).
4. Review of the main Web sites that maintain up-to-date
information on disease statistics for river blindness and
related diseases. These include:
# The WHO: http://www.who.int/topics/onchocerciasis/en/
# The Carter Center: http://www.cartercenter.org/health/
river_blindness/index.html
# Sightsavers: http://www.sightsavers.org/What%20We%20Do/
Eye%20Conditions/River%20Blindness/World1622.html
# Global Partnership to Eliminate Riverblindness: http://
www.worldbank.org/afr/gper/
Box 3. Learning Points
1. Although ivermectin has made an immense contribution
to onchocerciasis control, it cannot abrogate transmis-
sion, and its efficacy is threatened by emerging drug
resistance. Therefore, a drug that is effective against
adult worms, or a vaccine, is required.
2. Progress on understanding protective immunity in
onchocerciasis has been accelerated by two model
systems in particular, Litomosoides sigmodontis in mice
and Onchocerca ochengi in cattle.
3. In both mice and cattle, immunisation with irradiated
third-stage larvae (L3) induces significant protection,
providing proof-of-principle for a vaccine. In contrast,
drug-abbreviated infections fail to induce protective
immunity.
4. Onchocerca volvulus, O. ochengi, L. sigmodontis, and many
other filariae contain endosymbiotic bacteria (Wolba-
chia), which, if depleted by prolonged antibiotic chemo-
therapy, result in adult worm death. Shorter treatment
regimens involving drug combinations are being inves-
tigated.
5. Immunity against filarial parasites is complex, with Th2-
type mechanisms driving protection against L3 and
microfilariae, whilst both Th1 and Th2 pathways are
involved in resistance to adult worms. Parasite survival is
achieved by the induction of an immunoregulatory
milieu.
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